These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24298070)
21. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response. Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203 [No Abstract] [Full Text] [Related]
22. Immunotherapy of Breast Cancer. Criscitiello C; Curigliano G Prog Tumor Res; 2015; 42():30-43. PubMed ID: 26377084 [TBL] [Abstract][Full Text] [Related]
23. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Burugu S; Asleh-Aburaya K; Nielsen TO Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387 [TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519 [TBL] [Abstract][Full Text] [Related]
25. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923 [TBL] [Abstract][Full Text] [Related]
26. Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells. Gril B; Palmieri D; Qian Y; Anwar T; Liewehr DJ; Steinberg SM; Andreu Z; Masana D; Fernández P; Steeg PS; Vidal-Vanaclocha F Am J Pathol; 2013 Jun; 182(6):2368-79. PubMed ID: 23583652 [TBL] [Abstract][Full Text] [Related]
27. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Knutson KL; Block MS; Norton N; Erskine CL; Hobday TJ; Dietz AB; Padley D; Gustafson MP; Puglisi-Knutson D; Mangskau TK; Chumsri S; Dueck AC; Karyampudi L; Wilson G; Degnim AC Clin Cancer Res; 2020 Mar; 26(5):1045-1053. PubMed ID: 31757875 [TBL] [Abstract][Full Text] [Related]
28. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Kang TH; Mao CP; Lee SY; Chen A; Lee JH; Kim TW; Alvarez RD; Roden RB; Pardoll D; Hung CF; Wu TC Cancer Res; 2013 Apr; 73(8):2493-504. PubMed ID: 23418322 [TBL] [Abstract][Full Text] [Related]
29. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells. Ramachandran M; Dimberg A; Essand M Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957 [TBL] [Abstract][Full Text] [Related]
30. Current immunotherapeutic strategies in breast cancer. Carson WE; Liang MI Surg Oncol Clin N Am; 2007 Oct; 16(4):841-60, ix. PubMed ID: 18022548 [TBL] [Abstract][Full Text] [Related]
31. Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies. Medina-Echeverz J; Hinterberger M; Testori M; Geiger M; Giessel R; Bathke B; Kassub R; Gräbnitz F; Fiore G; Wennier ST; Chaplin P; Suter M; Hochrein H; Lauterbach H Nat Commun; 2019 Nov; 10(1):5041. PubMed ID: 31695037 [TBL] [Abstract][Full Text] [Related]
32. Checkpoint inhibitors in breast cancer: hype or promise? McArthur HL Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806 [No Abstract] [Full Text] [Related]
33. Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator. Yin T; Wang G; Ye T; Wang Y Sci Rep; 2016 Jan; 6():19534. PubMed ID: 26777116 [TBL] [Abstract][Full Text] [Related]
34. Immunizing against breast cancer: a new swing for an old sword. Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543 [TBL] [Abstract][Full Text] [Related]
35. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. Conte P; Guarneri V; Bengala C Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773 [TBL] [Abstract][Full Text] [Related]
36. How to improve the immunogenicity of chemotherapy and radiotherapy. Ma Y; Conforti R; Aymeric L; Locher C; Kepp O; Kroemer G; Zitvogel L Cancer Metastasis Rev; 2011 Mar; 30(1):71-82. PubMed ID: 21298323 [TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer. Sharma MC; Tuszynski GP; Blackman MR; Sharma M Cancer Lett; 2016 Apr; 373(1):27-35. PubMed ID: 26797420 [TBL] [Abstract][Full Text] [Related]
38. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition. Labanca V; Bertolini F EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898 [No Abstract] [Full Text] [Related]
39. Diverse macrophages polarization in tumor microenvironment. Rhee I Arch Pharm Res; 2016 Nov; 39(11):1588-1596. PubMed ID: 27562774 [TBL] [Abstract][Full Text] [Related]
40. Mechanisms of trastuzumab resistance in breast cancer. Tolaney SM; Krop IE Anticancer Agents Med Chem; 2009 Mar; 9(3):348-55. PubMed ID: 19275526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]